Jagsonpal Pharmaceuticals completes acquisition of Group Pharma’s Wellness Portfolio
As filed · Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Subsequent to fulfilment of the Conditions Precedent under the BTA the transaction has been consummated with effect from today i.
What happened
FactJagsonpal Pharmaceuticals said it completed the acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited on October 01, 2026. The transaction was consummated after the conditions precedent under the Business Transfer Agreement were fulfilled.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Order Book
DelayedWe are pleased with our FY25 performance, which underscores the strength of our strategy and execution.
Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting from now.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting (management committed by FY29)
- Starting with a revenue base of Rs.53 crores, we are targeting Rs.10 crores EBITDA by year two post-integratio (management committed by FY27)
Evidence
- Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Subsequent to fulfilment of the Conditions Precedent under the BTA the transaction has been consummated with effect from today i.e., October 01, 2026.'.(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- The completion moves the previously announced portfolio acquisition from agreement to execution, potentially expanding Jagsonpal’s business through the acquired wellness products. The filing does not disclose the transaction value or expected financial contribution.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%